Risk of post-discharge venous thromboembolism in patients with rheumatoid arthritis undergoing knee or hip arthroplasty. Is prolonged thromboprophylaxis warranted or dangerous?

Annals of the Rheumatic Diseases

Volumn 58, Issue 7, 1999, Pages 392-395

  Nurmohamed, M T ^a   Lems, W F ^a   Dijkmans, B A C ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; EDITORIAL; HIP ARTHROPLASTY; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; KNEE ARTHROPLASTY; NONHUMAN; PATHOGENESIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; RAT; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; THROMBOEMBOLISM;

EID: 0033013533     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.58.7.392     Document Type: Editorial

References (38)

1. 1 Salzman EW, Hirsh J. The epidemiology, pathogenesis and natural history of venous thrombosis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: JB Lippincott, 1994:1275-96.
2. 2 Abernethy PJ. Surgery of the rheumatoid knee. Ann Rheum Dis 1990;49:830-6.
3. 3 Kelly IG. Surgical treatment of the rheumatoid hip. Ann Rheum Dis 1990; 49:858-62.
4. 4 Cooke TDV. Orthopaedic conditions and surgery. Curr Opin Rheumatol 1992;4:179-83.
5. 5 Stringer MD, Steadman CA, Hedges AR, Thomas EM, Morley RM, Kakkar VV. Deep vein thrombosis after elective knee surgery - an incidence study in 312 patients. J Bone Joint Surg Br 1989;71:492-7.
6. 6 Sharrock NE, Hargett MJ, Urquhart B, Peterson MGE, Ranawat C, Insall J, et al. Factors affecting deep vein thrombosis rate following total knee arthroplasty under epidural anesthesia. J Arthroplasty 1993;8:133-9.
7. 7 White RH, McCurdy SA, Marder RA. Early morbidity after hip replacement: rheumatoid arthritis versus osteoarthritis. J Gen Intern Med 1990;5:304-9.
8. 8 Bachmann F, Leyvraz PF. Low-molecular-weight heparins for prevention of venous thromboembolism following orthopedic surgery. In: Bounameaux H, ed. Low molecular weight heparins in prophylaxis and therapy of thromboembolic diseases. New York: Marcel Dekker Inc, 1994:187-212.
9. 9 Kakkar VV. Low molecular weight heparins: prophylaxis of venous thromboembolism in surgical patients. Semin Hematol 1997;4 (suppl 4):9-19.
10. 10 Dahl OE, Aspelin T, Amersen H, Seljeflot I, Kierulf P, Ruyter R, et al. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res 1995;4:299-306.
11. 11 Nurmohamed MT, Rosendaal FR, Büller HR, Dekker E, Hommes DW, Vandenbroucke JP, et al. Low molecular weight heparin in general and orthopedic surgery: a meta-analysis. Lancet 1992;340:152-6.
12. 12 Nurmohamed MT, Cate H ten, Cate JW ten. Low molecular weight heparin(oid)s. Drugs 1997;53:736-51.
13. 13 Howard AW, Shawn SD. Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty. Thromb Haemost 1998;79:902-6.
14. 14 Swierstra BA, Stibbe J, Schouten HJA. Prevention of thrombosis after hip arthroplasty: a prospective study of preoperative oral anticoagulants. Acta Orthop Scand 1988;59:139-43.
15. 15 Büller HR, Lensing AWA, Hirsh J, ten Cate JW. Deep vein thrombosis: new non-invasive diagnostic tests. Thromb Haemost 1991;66:133-7.
16. 16 Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg J. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study in patients who underwent hip or knee arthroplasty. Arch Intern Med 1998;158:873-8.
17. 17 ten Cate JW, Prins MH. Major orthopaedic surgery and post-discharge DVT. Lancet 1996;348:209-10.
18. 18 Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. N Engl J Med 1982;307:1676-81.
19. 19 Landefeld CS, Goldman L. Bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87:144-52.
20. 20 Landefeld S, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 1993;95:315-28.
21. 21 Van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy. Arch Intern Med 1993;153: 1557-62.
22. 22 Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaboration study (ISCOAT); Lancet 1996;348:423-38.
23. 23 Kuijer PMM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. In: Kuijer PMM. Diagnostic and therapeutic management of pulmonary embolism. University of Amsterdam: Academic Thesis, 1997:131-41.
24. 24 Schulman S. Interaction of ibuprofen and warfarin on primary hemostasis. Br J Rheumatol 1989;28:46-9.
25. 25 Rodriguez L, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343;769-72.
26. 26 Bergqvist D. The postdischarge risk of venous thromboembolism after hip replacement: The role of prolonged prophylaxis. Drugs 1996;52 (suppl 7):55-9.
27. 27 Hirsh J. Evidence for the needs of out-of-hospital thrombosis prophylaxis: introduction. Chest 1998;114 (suppl):113-4S.
28. 28 Davidson BL. Out-of-hospital prophylaxis with low-molecular-weight heparin in hip surgery. Chest 1998;114 (suppl):I30-2S
29. 29 Thrombosis Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992;305:567-74.
30. 30 Doutremepuich F, Aguejouf O, Imbault P, Azougagh Oualane F, Doutremepuich C. Effect of low molecular weight heparin/non-steroidal antiinflammatory drugs association on an experimental thrombosis induced by laser. Thromb Res 1995;77:311-19.
31. 31 Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth GJ. Aspirin and other platelet-active drugs: The relationship between dose, effectiveness and side effects. Chest 1995;108 (suppl):247-57.
32. 32 Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1991;308;235-46.
33. 33 Cohen AT, Skinner JA, Kakkar VV. Antiplatelet treatment for thromboprophylaxis: a step forward or backwards. BMJ 1994;309:1213-17.
34. 34 Antiplatelet Trialists, Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
35. R). Thromb Haemost 1997;77:26-31.
36. 36 Lassen MR, Borris LC, Anderson BS, Jensen HP, Bro HPS, Andersen G, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (Dalteparin) after total hip arthroplasty. Thromb Res 1998;89:281-7.
37. 37 Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double blind randomised comparison of enoxaparin versus placebo. Lancet 1996;348:224-8.
38. 38 Bergqvist D, Benoni G, Björgell O, Fredin H, Hedlundh U, Nicolas S, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335: 696-700.